Evaluate the pharmaceutical company uptravi on generic?

Short answer: Uptravi is a brand name for selexipag, not a company. There is no widely available generic (unbranded) selexipag as of now.

What this means
- Uptravi (selexipag) is a prostacyclin receptor agonist used to treat pulmonary arterial hypertension (PAH). It’s developed by Actelion and, after Janssen’s acquisition, is marketed by Janssen Pharmaceuticals.
- As of my last update, there is no approved generic selexipag product in major markets. Generics would require patent expiration plus regulatory approval, and patent protections (plus potential exclusivities) are currently limiting generic entry.
- The exact timing for any potential generic would depend on jurisdiction and patent litigation outcomes, but in the US/EU it’s typically years away if patent rights remain in force.

How to evaluate if/when a generic might appear (practical steps)
- Check patent and exclusivity status:
- Look up the US FDA Orange Book for selexipag patents and listed exclusivities.
- Check the European Patent Office and national patent databases for timelines in your country/region.
- Monitor regulatory approvals:
- Search for any ANDA (abbreviated new drug application) approvals or generic filings in major markets.
- Consider regional differences:
- Some countries may grant local approvals or have different patent landscapes; an un-branded generic could appear regionally even if not approved elsewhere.
- Price and access:
- Generics typically reduce price significantly, but payor coverage and formulary status also influence patient access.

If you’d like, tell me your country/region and I can look up the current patent status and any active generic filings or approvals there. And if your interest is clinical (how selexipag works, dosing, safety) I can summarize that too.